Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 278, Issue 4 47-4, 2000, Pages

  Kuoppala, Antti ^a   Lindstedt, Ken A ^a   Saarinen, Juhani ^b   Kovanen, Petri T ^a   Kokkonen, Jorma O ^a,c  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Kininase I; Kininase II; Peptides

Indexed keywords

ARGININE CARBOXYPEPTIDASE; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ARTICLE; CARDIOVASCULAR AUTOREGULATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEART PROTECTION; HUMAN; MALE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0034009830     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.278.4.h1069     Document Type: Article

References (28)

1. Blaufarb IS and Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 77: 8C-16C, 1996.
2. 9-bradykinin in vitro and in vivo. Br J Pharmacol 92: 257-264, 1987.
3. Campbell DJ, Kladis A, and Duncan A-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21: 155-165, 1993.
4. 1 receptor. Br J Pharmacol 108: 318-322, 1993.
5. Danser JAH, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM, Saxena PR, and Schalekamp MADH. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 96: 220-226, 1997.
6. 9]BK: influence of enalaprilat. Am J Physiol Heart Circ Physiol 270: H1340-H1347, 1996.
7. Dendorfer A, Wolfrum S, Wellhöner P, Korsman K, and Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Br J Pharmacol 122: 1179-1187, 1997.
8. Dorer FE, Kahn JR, Lentz KE, Levine M, and Skeggs LT. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res 24: 824-827, 1974.
9. Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 56: 131-190, 1992.
10. Hasan AAK, Amenta S, and Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 94: 517-528, 1996.
11. Jaspard E, Wei L, and Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). J. Biol Chem 268: 9496-9503, 1993.
12. Kitamura S, Carbini LA, Simmons WH, and Scicli AG. Effects of aminopeptidase P inhibition on kinin-mediated vasodepressor responses. Am J Physiol Heart Circ Physiol 276: H1664-H1671, 1999.
13. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, and Kovanen PT. Kallidin-and bradykinin-degrading pathways in the human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 99: 1984-1990, 1999.
14. Kokkonen JO, Saarinen J, and Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 95: 1455-1463, 1997.
15. 1 receptors and development of a cellular model for the investigation of these receptors. Br J Pharmacol 109: 1254-1262, 1993.
16. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, and Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinin s and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997.
17. 9-BK in plasma. Can J Physiol Pharmacol 59: 131-138, 1981.
18. Marceau F and Regoli DC. Kinin receptors of the B1 type and their antagonists. In: Bradykinin Antagonists: Basic and Clinical Research, edited by Burch RM. New York: Dekker, 1991, p. 33-49.
19. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, and Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of cc nverting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91: 2043-2048, 1995.
20. 9]-bradykinin in low-renin essential hypertension-before and after treatment with enalapril (MK 421). J Lab Clin Med 102: 714-721, 1983.
21. Regoli D, Jukic D, Gobeil F, and Rhaleb N-E. Receptors for bradykinin and related kinins: a critical analysis. Can J Physiol Pharmacol 71: 556-567, 1993.
22. Schremmer-Danninger E, Öffner A, Siebeck M, Heinz-Erian P, Gais P, and Roscher AA. Autoradiographic visualization of B1 bradykinin receptors in porcine vascular tissues in the presence or absence of inflammation. Immunopharmacology 33: 95-100, 1996.
23. Sheikh IA and Kaplan AP. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Biochem Pharmacol 38: 993-1000, 1989.
24. Skidgel RA, Deddish PA, and Davis RM. Isolation and characterization of a basic carboxypeptidase from human seminal plasma. Arch Biochem Biophys 267: 660-667, 1988.
25. Skidgel RA, Johnson AR, and Erdös EG. Hydrolysis of opioid hexapeptides by carboxypeptidase N. Biochem Pharmacol 33: 3471-3478, 1984.
26. Stewart TA, Weare JA, and Erdös EG. Purification and characterization of human converting enzyme (kininase II). Peptides 2: 145-152, 1981
27. Sybertz EJ, Chiu PJS, Vemulapalli S, Pitts B, Foster CJ, Watkins RW, Barnett A, and Haslanger MF. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 250: 624-631, 1989
28. Wollert KC, Studer R, Doefer K, Schieffer E, Holubarsch C, Just H, and Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 95: 1910-1917, 1997